Sanofi Gross Margin 2010-2024 | SNY

Current and historical gross margin for Sanofi (SNY) over the last 10 years. The current gross profit margin for Sanofi as of March 31, 2024 is %.
Sanofi Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2024-03-31 $50.68B $34.84B 68.75%
2023-12-31 $50.27B $34.86B 69.35%
2023-09-30 $49.01B $34.08B 69.53%
2023-06-30 $48.42B $33.81B 69.83%
2023-03-31 $48.20B $33.70B 69.91%
2022-12-31 $47.82B $33.39B 69.83%
2022-09-30 $48.72B $34.35B 70.51%
2022-03-31 $34.76B $24.48B 70.41%
2021-09-30 $35.03B $24.26B 69.26%
2021-03-31 $43.57B $29.98B 68.80%
2020-09-30 $42.75B $29.42B 68.82%
2020-03-31 $41.19B $28.45B 69.06%
2019-09-30 $41.49B $28.27B 68.15%
2019-03-31 $41.50B $28.41B 68.47%
2018-03-31 $41.43B $28.14B 67.93%
2017-12-31 $40.92B $27.80B 67.93%
2017-09-30 $40.25B $27.56B 68.47%
2017-06-30 $39.59B $27.15B 68.59%
2017-03-31 $39.14B $27.03B 69.06%
2016-12-31 $38.41B $26.57B 69.17%
2016-09-30 $39.27B $27.29B 69.49%
2016-06-30 $39.37B $27.23B 69.17%
2016-03-31 $41.16B $28.29B 68.75%
2015-09-30 $42.97B $29.31B 68.22%
2015-06-30 $43.92B $30.08B 68.50%
2014-06-30 $44.70B $30.67B 68.62%
2013-06-30 $45.22B $31.02B 68.59%
2012-06-30 $46.75B $31.94B 68.33%
2012-03-31 $47.10B $31.70B 67.31%
2011-12-31 $47.27B $32.09B 67.88%
2011-09-30 $45.65B $31.06B 68.05%
2011-06-30 $44.35B $30.90B 69.68%
2011-03-31 $42.93B $30.94B 72.07%
2010-12-31 $41.26B $29.68B 71.95%
2010-09-30 $41.28B $29.76B 72.09%
2010-06-30 $41.42B $29.96B 72.33%
2010-03-31 $41.35B $30.02B 72.59%
2009-12-31 $40.79B $29.80B 73.06%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $119.456B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Innoviva (INVA) United States $1.013B 7.11